Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Lung Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Advanced Solid Tumors 1

Interventions

pembrolizumab 44Paclitaxel 37Carboplatin 30Doxorubicin 11Cisplatin 11Bevacizumab 11lenvatinib 9Nivolumab 9Docetaxel 9Fulvestrant 8Gemcitabine 7Oxaliplatin 6Fluorouracil 6Pemetrexed 5Letrozole 5Ipilimumab 5Cetuximab 5spartalizumab 4selinexor 4dostarlimab 4Trastuzumab 4Irinotecan 4trastuzumab deruxtecan 3tisotumab vedotin 3serabelisib 3sacituzumab govitecan 3ribociclib 3olaparib 3epacadostat 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Endometrial Neoplasms × E-3810 × Clear all
NCT04042116 2022-12-20

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Clovis Oncology, Inc.

Phase 1/2 Suspended
227 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡